Dear Prof CERASALE MORTEO,
We would like to recommend a selection of our highly accessed articles from Journal for ImmunoTherapy of Cancer.
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
We hope that you find the articles below of interest and invite you to submit your next manuscript to the journal.
The Society for Immunotherapy of Cancer (SITC) has recently published guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma, as part of the Cancer Immunotherapy Guidelines series.
These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.
The BioMed Central Team
PS. Visit our website to find out more about open access funding options that may be available to you.
OFFICIAL JOURNAL OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)
miércoles, 17 de mayo de 2017
Don't miss out on our latest Highly Accessed Articles | Journal for ImmunoTherapy of Cancer
For further information or enquiries please contact Customer Services at:email@example.com.
BioMed Central Ltd
236 Gray's Inn Road, London, WC1X 8HB,